Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy

Musi, Marco; Carbone, Roberto; Bertocchi, Cesare; Cantalupi, D; Michetti, Giovanni; Pugliese, Cristina; Virotta, Giorgio

doi:10.1016/s0169-5002(98)00075-0

Cited by 66 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Flushing and diarrhoea are mainly reported in those whose tumours are more than 5 cm in diameter or who have liver metastases, and our findings are consistent with the published data [11]. In our experience, Octreoscan is effective in detecting the primary tumour at diagnosis, increasing with tumour size, local recurrence and distant metastases, in both TCs and ACs [24]. …”

Section: Discussionsupporting

confidence: 90%

“…Our analysis suggests that the first-line therapy for typical and atypical bronchial syndromic carcinoids, like that for well-differentiated gastrointestinal NETs, should be a somatostatin analogue. The effect of interferon-α on pulmonary carcinoids is disappointing, but in some cases can significantly improve symptoms, while its effect on tumour growth seems to be limited [18, 24, 26]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary Carcinoid Tumours: Indolent but Not Benign

Dosso¹,

Bajetta²,

Procopio³

et al. 2007

Oncology

View full text Add to dashboard Cite

Background: The aim of this retrospective study was to analyse the malignant behaviour of low-grade pulmonary neuroendocrine tumours (NETs) treated at our institution. Patients and Methods: We reviewed 48 consecutive patients with pulmonary NETs referred to our Medical Oncology Unit between 1998 and 2006, including 33 subjects with typical carcinoids (TCs) and 15 with atypical carcinoids (ACs). Results: At diagnosis, there were 37 metastatic and 11 non-metastatic patients. Medical treatments used were somatostatin analogues, combined chemotherapy, within study protocols, 5-fluorouracil/dacarbazine/epiadriamycin (FDE), and oxaliplatin plus capecitabine (XELOX). Median disease-free survival was 72 months for the TC patients and 38 months for the AC patients. Actuarial 5-year survival was 93% for those with TCs and 73% for those with ACs. The mean overall survival was 68 months for the non-metastatic patients (78 months for TC patients and 58 months for AC patients) and 36 months for patients with advanced disease (42 and 32 months, respectively). Conclusion: Cell type is the strongest determinant of prognosis, and the degree of malignancy increases from TCs to ACs. Moreover, the prognosis of metastatic pulmonary carcinoids is not as good as expected. Our analysis suggests that patients with advanced disease should receive first-line therapy with a somatostatin analogue, with chemotherapy regimens (FDE, XELOX) used in progressing cases.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Pulmonary Carcinoid Tumours: Indolent but Not Benign

Dosso¹,

Bajetta²,

Procopio³

et al. 2007

Oncology

View full text Add to dashboard Cite

show abstract

“…Octreoscan has a sensitivity of 96.3% and is shown to be a very useful imaging tool when used in conjunction with CT. Similar sensitivities for Octreoscan in foregut and bronchial carcinoids have been reported in other studies [20,21]. FDG-PET was 55.6% sensitive in this study, however, was only used in nine cases.…”

Section: Discussionsupporting

confidence: 88%

Surgical management and palliative treatment in bronchial neuroendocrine tumours: A clinical study of 45 patients

et al. 2009

View full text Add to dashboard Cite

“…53,55 In patients with bronchial GEP ETs that lead to Cushing's syndrome, somatostatin receptor scintigraphy sensitivity ranges from 33% to 100% for depiction of the primary tumor. 25, 56 In patients with MEN1, multiple GEP ETs should not be confused with a metastatic spread.…”

Section: Stagingmentioning

confidence: 99%

“…47,53,55,56 Somatostatin receptor scintigraphy complements conventional imaging for extrahepatic abdomen, bone, and mediastinum staging; conventional imaging is more sensitive than somatostatin receptor scintigraphy for depiction of lung, liver, and brain metastases. 52,57 In addition, somatostatin receptor scintigraphy is expected to predict the efficiency of radio nuclide therapy aimed at somatostatin receptors and to evaluate its effects.…”

Section: Stagingmentioning

confidence: 99%

Gastroenteropancreatic endocrine tumors: clinical characterization before therapy

Baudin

2007

Nat Rev Endocrinol

View full text Add to dashboard Cite

Gastroenteropancreatic endocrine tumors (GEP ETs) constitute a spectrum of tumors that arise throughout the entire body but are drawn together under a common definition based on the expression of proteins derived from granules, vesicles, or both. GEP ET characterization is dependent on the primary tumor, and encompasses various factors: the WHO classification; hormone-related symptom recognition; hormone marker measurements; screening for inherited syndromes; staging; and somatostatin receptor characterization. Hypervascularization and somatostatin expression constitute major features of endocrine tumors that affect diagnosis, imaging, and therapy. GEP ET prognosis is characterized by its diversity, including a subgroup of patients with slowly progressive disease even at the metastatic stage. Prognosis assessment is mainly based on WHO classification and staging. A second cancer and cardiovascular comorbidity might also play a major prognostic part when present. Mastery of several key points analyzed in this Review, to be applied during the diagnostic and prognostic processes, is essential for defining a tailored therapeutic management.

show abstract

Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy

Cited by 66 publications

References 24 publications

Pulmonary Carcinoid Tumours: Indolent but Not Benign

Pulmonary Carcinoid Tumours: Indolent but Not Benign

Surgical management and palliative treatment in bronchial neuroendocrine tumours: A clinical study of 45 patients

Gastroenteropancreatic endocrine tumors: clinical characterization before therapy

Contact Info

Product

Resources

About